
    
      A non-randomised, open label, single-arm phase II study to evaluate the efficacy and safety
      of 1st-line pazopanib followed by 2nd-line everolimus in patients with previously untreated
      advanced or metastatic renal cell carcinoma. Subjects received initial therapy with pazopanib
      followed, on progression, by 2nd-line therapy with everolimus. Study treatment - sequential
      treatment with pazopanib followed by everolimus - to continue until disease progression,
      unacceptable toxicity, withdrawal of consent, or death.
    
  